Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2025 Mar;26(2):93-103.e1.
doi: 10.1016/j.cllc.2024.11.003. Epub 2024 Nov 20.

Clinical, Dosimetric and Radiomic Features Predictive of Lung Toxicity After (Chemo)Radiotherapy

Affiliations
Multicenter Study

Clinical, Dosimetric and Radiomic Features Predictive of Lung Toxicity After (Chemo)Radiotherapy

Cécile Evin et al. Clin Lung Cancer. 2025 Mar.

Abstract

Background: Treatment of locally advanced non small cell lung cancer (LA-NSCLC) is based on (chemo)radiotherapy, which may cause acute lung toxicity: radiation pneumonitis (RP). Its frequency seems to increase by the use of adjuvant durvalumab therapy.

Aims: To identify clinical, dosimetric, and radiomic factors associated with grade (G)≥2 RP and build a prediction model based on selected parameters.

Patients and methods: This is a retrospective multicenter cohort study including patients receiving radiation therapy between 2015 and 2019 for LA-NSCLC. Baseline computed tomography scanners were segmented to extract radiomic features from the "Lung - Tumor" volume. Variables associated with the risk of G≥2 RP in the descriptive analysis were then selected for explanatory analysis, followed by predictive analysis.

Results: 153 patients were included in 4 centers (51 with G≥2 RP). Factors associated with G≥2 RP included a high initial hemoglobin level, dosimetric factors (mean dose to healthy lungs, lung V20Gy and V13Gy), the addition of maintenance durvalumab, and 7 radiomic features (intensity distribution and texture). Other factors were associated with an increased risk of G≥2 RP in our explanatory model, such as older age, low Tiffeneau ratio, and a decreased initial platelet count. The best-performing predictive model was a random forest-based learning model using clinical, dosimetric, and radiomic variables, with an area under the ROC curve of 0.72 (95%CI [0.63; 0.80]) versus 0.64 for models using one type of data.

Conclusion: The addition of radiomic features to clinical and dosimetric ones improves prediction of the occurrence of G≥2 RP in patients receiving radiotherapy for lung cancer.

Keywords: Artificial intelligence; Lung cancer; Radiation pneumonitis; Radiation therapy; Radiomics.

PubMed Disclaimer

Conflict of interest statement

Disclosure Cécile Evin: Merck, Léo Razakamanantsoa : none, François Gardavaud: none, Léa Papillon: employed by SOPHiA GENETICS, Hamza Boulaala: employed by SOPHiA GENETICS, Loïc Ferrer: employed by SOPHiA GENETICS, Olivier Gallinato: employed by SOPHiA GENETICS, Thierry Colin: employed by SOPHiA GENETICS, Sondos Ben Moussa: none, Yara Harfouch: none, Jean-Noël Foulquier: none, Sophie Guillerm: none, Jean-Emmanuel Bibault: none, Florence Huguet : BMS, Merck, MSD, Amgen, Mathilde Wagner: none, Eleonor Rivin del Campo: none.

Publication types

MeSH terms